David Turkaly
Stock Analyst at Citizens Capital Markets
(2.38)
# 2,394
Out of 4,784 analysts
148
Total ratings
40.58%
Success rate
-1.1%
Average return
Main Sectors:
Stocks Rated by David Turkaly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TELA TELA Bio | Maintains: Market Outperform | $12 → $7 | $1.24 | +466.80% | 6 | Mar 21, 2025 | |
| KIDS OrthoPediatrics | Reiterates: Market Outperform | $50 | $24.74 | +102.10% | 10 | Mar 21, 2025 | |
| AXGN Axogen | Reiterates: Market Outperform | $26 | $18.36 | +41.61% | 7 | Mar 5, 2025 | |
| IART Integra LifeSciences Holdings | Reiterates: Market Outperform | $35 | $21.69 | +61.36% | 14 | Feb 26, 2025 | |
| SIBN SI-BONE | Reiterates: Market Outperform | $32 | $14.04 | +127.92% | 7 | Feb 25, 2025 | |
| GMED Globus Medical | Reiterates: Market Perform | n/a | $72.55 | - | 2 | Feb 24, 2025 | |
| SYK Stryker | Maintains: Market Perform | n/a | $364.50 | - | 2 | Feb 18, 2025 | |
| HAE Haemonetics | Maintains: Market Outperform | $125 → $100 | $63.19 | +58.25% | 11 | Feb 7, 2025 | |
| SNAP Snap Inc. | Reiterates: Market Outperform | $16 | $8.89 | +79.98% | 1 | Jan 29, 2025 | |
| LNTH Lantheus Holdings | Reiterates: Market Outperform | $112 | $96.16 | +16.47% | 8 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $223.00 | +18.83% | 16 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $5.84 | - | 14 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $62 | $37.76 | +64.19% | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $1.30 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $3 | $3.77 | -20.42% | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $23 → $20 | $13.04 | +53.37% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $16.06 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $285 | $137.80 | +106.82% | 14 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $160 → $140 | $112.26 | +24.71% | 13 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $4 | $2.14 | +86.92% | 4 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $7.95 | -37.11% | 1 | Oct 6, 2017 |
TELA Bio
Mar 21, 2025
Maintains: Market Outperform
Price Target: $12 → $7
Current: $1.24
Upside: +466.80%
OrthoPediatrics
Mar 21, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $24.74
Upside: +102.10%
Axogen
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $26
Current: $18.36
Upside: +41.61%
Integra LifeSciences Holdings
Feb 26, 2025
Reiterates: Market Outperform
Price Target: $35
Current: $21.69
Upside: +61.36%
SI-BONE
Feb 25, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $14.04
Upside: +127.92%
Globus Medical
Feb 24, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $72.55
Upside: -
Stryker
Feb 18, 2025
Maintains: Market Perform
Price Target: n/a
Current: $364.50
Upside: -
Haemonetics
Feb 7, 2025
Maintains: Market Outperform
Price Target: $125 → $100
Current: $63.19
Upside: +58.25%
Snap Inc.
Jan 29, 2025
Reiterates: Market Outperform
Price Target: $16
Current: $8.89
Upside: +79.98%
Lantheus Holdings
Jan 14, 2025
Reiterates: Market Outperform
Price Target: $112
Current: $96.16
Upside: +16.47%
Nov 18, 2024
Reiterates: Market Outperform
Price Target: $265
Current: $223.00
Upside: +18.83%
Nov 12, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $5.84
Upside: -
Oct 3, 2024
Initiates: Market Outperform
Price Target: $62
Current: $37.76
Upside: +64.19%
Sep 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $1.30
Upside: -
Aug 14, 2024
Maintains: Market Outperform
Price Target: $7 → $3
Current: $3.77
Upside: -20.42%
May 9, 2024
Maintains: Market Outperform
Price Target: $23 → $20
Current: $13.04
Upside: +53.37%
Apr 22, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $16.06
Upside: -
Feb 23, 2024
Reiterates: Market Outperform
Price Target: $285
Current: $137.80
Upside: +106.82%
Nov 13, 2023
Maintains: Market Outperform
Price Target: $160 → $140
Current: $112.26
Upside: +24.71%
Apr 13, 2023
Maintains: Outperform
Price Target: $7 → $4
Current: $2.14
Upside: +86.92%
Oct 6, 2017
Initiates: Outperform
Price Target: $5
Current: $7.95
Upside: -37.11%